Prestige Consumer Healthcare Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and first nine months ended December 31, 2023. The company develops, manufactures, markets and distributes OTC healthcare products in North America and selected international markets. Financial statements are unaudited.
Financial performance
- Third quarter: Total revenue was $282.7 million, up 2.6% year over year. Gross profit was $157.9 million (55.9% margin, versus 54.6%); operating income was $86.8 million, down 0.4%; net income was $53.0 million, up 2.1%. Diluted EPS was $1.06, versus $1.04.
- Nine months: Total revenue was $848.4 million, up 0.8%. Gross profit was $472.6 million (55.7% margin, versus 56.0%); operating income was $260.3 million, up 0.7%; net income was $159.9 million, up 1.0%. Diluted EPS was $3.19, versus $3.14.
- Operating costs and interest: Third-quarter advertising and marketing expense rose to $39.5 million from $30.4 million. Nine-month expense was $115.8 million, versus $114.2 million. Nine-month net interest expense increased to $51.9 million from $50.2 million as the average borrowing cost rose to 5.4% from 4.5%, despite lower average debt.
- Cash flow: Nine-month operating cash flow was $182.0 million, up from $170.7 million. Capital expenditures were $6.4 million; operating cash flow less capital expenditures was approximately $175.6 million. Cash increased $5.1 million from fiscal year-end to $63.6 million.
- Debt and liquidity: Gross debt was $1.21 billion, including $1.00 billion of senior notes and $210 million of term loans; cash was $63.6 million. The ABL revolver had no borrowings and $168.9 million of borrowing capacity. The company reported compliance with debt covenants and said cash from operations and existing credit facilities should cover working capital and capital expenditures for the next 12 months, excluding acquisitions.
Changes versus prior comparable periods
- Quarterly revenue growth was led by International OTC Healthcare, up 19.5%; North American OTC Healthcare was nearly flat, down 0.1%. International growth was strongest in gastrointestinal, eye and ear care, and women’s health. North American eye and ear care increased, while cough and cold declined.
- For the nine months, International revenue rose 9.8%, while North American revenue declined 0.6%. North American women’s health, analgesics and cough and cold were among the categories contributing to the decrease.
- Quarterly gross margin improved, primarily from lower North American logistics costs. Nine-month gross margin edged down, as increased supply-chain costs and product mix more than offset pricing actions. International gross margin declined in both periods, reflecting supply-chain costs and mix.
- Operating cash flow improved primarily due to lower working-capital use. Financing cash outflow increased to $172.6 million from $105.4 million, principally reflecting higher net debt repayments; share repurchases under the company program fell to $25 million from $50 million.
Outlook, risks and notable items
- The filing provides no specific earnings or revenue guidance. Management expects volatile and uncertain economic conditions, with potential pressure on prices, supply and demand. It reported no material aggregate adverse impact to date, but warned further supply-chain, labor, input-cost or geopolitical disruptions could materially affect operations, liquidity and results.
- On December 8, 2023, the company amended its ABL revolver, increasing commitments from $175 million to $200 million, extending maturity to December 8, 2028, and adding flexibility for certain restricted payments, debt incurrence and borrowing-base calculations.
- Approximately 17.0% of quarterly and 14.1% of nine-month gross revenue was denominated in currencies other than the U.S. dollar. A hypothetical 1% rise in variable interest rates would have increased pre-tax interest costs by approximately $0.7 million for the quarter and $2.3 million for the nine months.
- Customer and supply concentration are relevant risks: Walmart represented 19.0% of quarterly and 19.6% of nine-month gross revenue; Amazon represented 10.7% and 10.4%, respectively. One primary U.S. distribution center and reliance on third-party manufacturers also create disruption risks.
- The company reported no current-period impairment indicators. It had recorded goodwill and intangible-asset impairment charges of $48.8 million and $321.4 million, respectively, in fiscal 2023; future impairment remains possible if assumptions such as sales, margins or discount rates deteriorate. Routine legal matters were not expected to have a material effect.
- The company repurchased $25 million of shares under its fiscal 2024 authorization, completed in the first quarter. No common-stock dividends had been declared or paid through December 31, 2023. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Key facts for investors to verify
- Whether revenue growth, particularly in international markets, continues and offsets softness in North American categories.
- Whether gross-margin pressure from supply-chain costs and product mix persists, and how higher advertising spending affects contribution margins.
- Debt paydown, variable-rate exposure, revolver availability and continued compliance with financial covenants.
- Customer concentration, third-party manufacturing and distribution dependencies, and the effect of economic or supply disruptions on demand and product availability.
- Whether the assumptions supporting goodwill and intangible-asset values remain reasonable in light of sales, margins, competition and interest rates.